Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva + Avastin vs Avastin in Metastatic RCC
NCT00081614Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic renal cell carcinoma (mRCC) comparing Tarceva + Avastin with Avastin + Placebo (2 arms). Primary endpoint: Time to Progression. Started Mar 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00081614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081614.